Patterns of infliximab use among Crohn's disease patients in a community setting

Alice R. Pressman, Susan Hutfless, Fernando Velayos, Bruce Fireman, James D. Lewis, James Allison, Oren Abramson, Lisa J. Herrinton

Research output: Contribution to journalArticle

Abstract

Background: Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members. Methods: The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis. Results: Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P <0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab. Conclusions: In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.

Original languageEnglish (US)
Pages (from-to)1265-1272
Number of pages8
JournalInflammatory Bowel Diseases
Volume14
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Crohn Disease
Comorbidity
Odds Ratio
Confidence Intervals
Infliximab
Survival Analysis
Cohort Studies
Logistic Models
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • Computerized medical information
  • Crohn's disease
  • Health services research
  • Infliximab
  • Variation in care

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Pressman, A. R., Hutfless, S., Velayos, F., Fireman, B., Lewis, J. D., Allison, J., ... Herrinton, L. J. (2008). Patterns of infliximab use among Crohn's disease patients in a community setting. Inflammatory Bowel Diseases, 14(9), 1265-1272. https://doi.org/10.1002/ibd.20483

Patterns of infliximab use among Crohn's disease patients in a community setting. / Pressman, Alice R.; Hutfless, Susan; Velayos, Fernando; Fireman, Bruce; Lewis, James D.; Allison, James; Abramson, Oren; Herrinton, Lisa J.

In: Inflammatory Bowel Diseases, Vol. 14, No. 9, 09.2008, p. 1265-1272.

Research output: Contribution to journalArticle

Pressman, AR, Hutfless, S, Velayos, F, Fireman, B, Lewis, JD, Allison, J, Abramson, O & Herrinton, LJ 2008, 'Patterns of infliximab use among Crohn's disease patients in a community setting', Inflammatory Bowel Diseases, vol. 14, no. 9, pp. 1265-1272. https://doi.org/10.1002/ibd.20483
Pressman, Alice R. ; Hutfless, Susan ; Velayos, Fernando ; Fireman, Bruce ; Lewis, James D. ; Allison, James ; Abramson, Oren ; Herrinton, Lisa J. / Patterns of infliximab use among Crohn's disease patients in a community setting. In: Inflammatory Bowel Diseases. 2008 ; Vol. 14, No. 9. pp. 1265-1272.
@article{9a8ddba3b1f5431d97583838fed05a86,
title = "Patterns of infliximab use among Crohn's disease patients in a community setting",
abstract = "Background: Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members. Methods: The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis. Results: Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P <0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95{\%} confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20{\%} of patients remained on infliximab. Conclusions: In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.",
keywords = "Computerized medical information, Crohn's disease, Health services research, Infliximab, Variation in care",
author = "Pressman, {Alice R.} and Susan Hutfless and Fernando Velayos and Bruce Fireman and Lewis, {James D.} and James Allison and Oren Abramson and Herrinton, {Lisa J.}",
year = "2008",
month = "9",
doi = "10.1002/ibd.20483",
language = "English (US)",
volume = "14",
pages = "1265--1272",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Patterns of infliximab use among Crohn's disease patients in a community setting

AU - Pressman, Alice R.

AU - Hutfless, Susan

AU - Velayos, Fernando

AU - Fireman, Bruce

AU - Lewis, James D.

AU - Allison, James

AU - Abramson, Oren

AU - Herrinton, Lisa J.

PY - 2008/9

Y1 - 2008/9

N2 - Background: Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members. Methods: The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis. Results: Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P <0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab. Conclusions: In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.

AB - Background: Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members. Methods: The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis. Results: Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P <0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab. Conclusions: In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.

KW - Computerized medical information

KW - Crohn's disease

KW - Health services research

KW - Infliximab

KW - Variation in care

UR - http://www.scopus.com/inward/record.url?scp=54349090370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349090370&partnerID=8YFLogxK

U2 - 10.1002/ibd.20483

DO - 10.1002/ibd.20483

M3 - Article

C2 - 18452199

AN - SCOPUS:54349090370

VL - 14

SP - 1265

EP - 1272

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -